GLP-1 receptor agonists have become an integral part of diabetes management, especially for type 2 diabetes, due to their ability to regulate blood sugar levels, promote weight loss, and improve overall glycemic control
Table of Contents Comparison Table: Tirzepatide vs Semaglutide at a Glance Clinical Effectiveness: What the Research Shows
If your prescriber or pharmacist is not familiar with the Bridge program, theres a website for them here
Case study I am 58, obese (BMI 35), with pre-diabetes (borderline Type 2), hypothyroidism (on 50 microg thyroxine), high cholesterol, and multiple sclerosis
Starting at $169/mo Physician monitored Physician guided Ongoing, adjusted over time Physician determined subcutaneous injection Medication, clinician, follow-ups What you can expect TWO PATHWAYS
In the relevance column it says GLP-1 cardiovascular benefits are documented in trials and may align with those risk changes